1Nickel JC, Teichman JM, Gregoire M, et al. Prevalence, diagno- sis, characterization, and treatment of prostatitis, interstitial cys- titis, and epididymitis in outpatient urological practice:the Ca- nadian PIE Study[ J ]. Urology,2005,66 (5) :935 - 940.
2Nickel JC, Nyberg LM, Hennenfent M. Research guidelines Ibr chronic prostatitis:consensus report from the first National Insti- tutes of Health International Prostatitis Collaborative Network [ J ]. Urology,54 (2) :229 - 233.
3Litwin MS, McNaughton - Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network [ J ]. J Urol, 1999, 162(2) :369 -375.
4Liang CZ, Li H J, Wang ZP, et al. Treatment of chronic prostatitis in Chinese men F .13. Asian J Androl.2009.11 (2) : 153 - 156.
5Clark K A,O'Driscoll C,Cooke C A,et al.Evaluation of the interactions between muhiwalled carbon nanotubes and Caco-2 cells.J Toxicol Environ Health A,2012,75(1):25-35.
6Vogl A W,Young J S,Du M.New insights into roles of tubulobulbar complexes in sperm release and turnover of blood-testis barrier.Int Rev Cell Mol Biol,2013,303:319-55.
7Cheng C Y,Mruk D D.The blood-testis barrier and its implications for male contraception.Pharmacol Rev.,2012,64( 1 ): 16-64.
8Lustig G,Ryan C M,Secor W E,et al.Trichomonas vaginalis contact-dependent cytolysis of epithelial cells.Infect Immun,2013,81(5):1411-1419.
9Fulmer B R, Turner T T.A blood-prostate barrier restricts cell and molecular movement across the rat ventral prostate epithelium.J Urol,2000,163(5):1591 - 1594.
10Chen Y,Liu X,Pan R,et al.Intestinal transport of 3,6'- disinapoylsucrose,a major active component of polygala tenuifolia,using caco-2 cell monolayer and in situ rat intestinal perfusion models.Planta Med,2013,79(15):1434-1439.
